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Summary
Background Existing treatments for asthma are not effective in all patients and disease
exacerbations are common, highlighting the need for increased understanding of disease
mechanisms and novel treatment strategies. The leukotriene pathway including the enzyme
responsible for arachidonic acid release from cellular phospholipids, cPLA2a, is a major
contributor to asthmatic responses and an attractive target in asthma therapies.
Objective The study reported here investigates (a) the differential effects of in vitro exposure of
peripheral blood mononuclear cells (PBMCs)to allergen between asthma and healthy subjects,
and (b) the contribution of cPLA2a to these differences in gene expression.
Methods In vitro responses of asthma (N=26) and healthy (N=11) subject PBMC samples to
allergen stimulation in the presence and absence of cPLA2a inhibition or 5-lipoxygenase
inhibition were compared at the gene expression level using oligonucleotide arrays and at the
protein level using ELISA.
Results Subject samples within both asthma and healthy groups showed allergen-dependent
cytokine production and allergen-dependent gene expression changes, although
transcriptional proﬁling identiﬁed 153 genes that were modulated signiﬁcantly differently by
allergen between asthma and healthy subjects. Among these were genes previously associated
with asthma, but the majority (about 80%) have not previously been associated with asthma.
Conclusions Transcriptional proﬁling elucidated novel gene expression differences between
the asthmatic and healthy subject samples. Although 5-lipoxygenase inhibition did not
signiﬁcantly affect allergen-modulated gene expression, the inhibition of cPLA2a activity
affected many of the allergen-dependent, asthma-associated gene expression changes.
Keywords asthmatic response to allergen, cPLA2a inhibition, differential gene expression in
asthma, transcriptional proﬁling
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Introduction
Asthma is a complex airway disease characterized by
reversible airway obstruction, bronchial hyperresponsive-
ness and airway inﬂammation. The prevalence of asthma
has almost doubled in the past 20 years, with approxi-
mately 8–10% of the US population effected by the disease
[1]. World-wide, over four billion dollars is spent on
treating asthma patients each year [2]. Current asthma
treatments target known disease mechanisms, but these
treatments are not effective in all patients and suboptimal
disease control among patients taking these medications
is common. Additional insight into the pathogenesis and
aetiology of asthma will facilitate development of more
widely effective therapies.
Asthma and Rhinitis
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a common mechanism underlying the pathophysiology of
asthma involves a dysregulated inﬂammatory response
in the lung to environmental allergens. This ultimately
results in increased vascular permeability, smooth mus-
cle contraction, bronchoconstriction and inﬂammation.
Asthma treatments currently available are designed to
inhibit these physiologic processes. Corticosteriods and
anti-allergy medicines, such as soluble IgE antibody
(Xolair
s) focus on inhibiting the dysregulated inﬂamma-
tory response. A major characteristic of the inﬂammatory
response is a shift in the balance of the immune response
from a T-helper type 1 (Th1) to a Th2 cytokine proﬁle [3].
Th2 cells mediate the inﬂammatory response through the
release of cytokines including ILs, particularly IL-13 [4, 5]
and IL-4 [6, 7] leading to IgE production and release [8]
and therapies targeting these mediators are being devel-
oped. Other treatments counter bronchial airway narrow-
ing, such as the bronchodilator salbutamol (Ventolin
s),
a short-acting b2-agonist [9, 10].
Reﬂecting the complexity of the disease, the therapies
described above, and others currently available, do not
consistently abrogate airway inﬂammation and airway
remodelling in all patients [11]. Inter-individual variabil-
ity in drug response [12–14] and frequent adverse drug
reactions [15–17] to currently available drugs necessi-
tate novel treatment strategies. Prior in vitro and in vivo
studies have elucidated some critical mechanisms of
asthma pathogenesis including the identiﬁcation of some
important mediators of allergen responsiveness. Previous
studies on the differences between asthma and healthy
subjects with respect to in vitro peripheral blood mono-
nuclear cell (PBMC) response to allergen have focused on
relatively well-characterized mediators such as IL-9 [18],
IL-5 and IL-4 [19], IL-13 [20], IL-10 [21] and IFN-g [22,
23]. Although these ﬁndings are informative, they provide
information for only a limited set of inﬂammatory targets
based on known disease pathways.
A global transcriptional proﬁling study was designed to
identify differentially responsive genes in PBMCs of
asthma and healthy subjects following in vitro allergen
challenge. This approach was aimed at facilitating the
discovery of novel biomarkers and therapeutic candidates
by revealing associations independent of an experimental
system guided by prior knowledge. Cytokine production
as assessed at the protein level by ELISAs was done in
parallel to allow comparisons with established methods of
assessing in vitro responsiveness. Additionally, transcrip-
tional proﬁling was carried out to determine the effect of
inhibition of cPLA2a on the in vitro allergen response of
asthma and healthy subjects. The cPLA2a enzyme is an
attractive target for inhibition in treatment of inﬂamma-
tory diseases; the enzyme selectively releases arachidonic
acid from cell membrane phospholipids to initiate the
production of lipid mediators of inﬂammation including
PGD2 and leukotrienes [24, 25]. In vivo inhibitors of
cPLA2a have been shown to prevent the development
of airway hyperresponsiveness (AHR) in a mouse model of
asthma [26] and the cPLA2a inhibitor tested in the study
reported here (WAY-196025) has shown efﬁcacy in the
sheep model of asthma [27]. In addition, antigen-speciﬁc
in vitro T cell responses are deﬁcient in cPLA2a knock-out
mice [28]. Evidence indicates that downstream products of
cPLA2 activity enhance inﬂammatory responses. LTs
enhance phagocytic capacity and the generation of pro-
inﬂammatory mediators by leucocytes [29]. cPLA2 also
generates the lysophospholipid precursor of PAF – a lipid
mediator of inﬂammation [30]. The potent chemoattrac-
tant activity of LTB4 for myeloid cells and T effector cells
[29, 31–33] also points to an important role in pro-
inﬂammatory cascades. Together, these ﬁndings prompted
the testing of a cPLA2a inhibitor on the allergen-speciﬁc in
vitro response associated with asthma.
Methods
Analytical samples
Twenty atopic and six non-atopic adult subjects with
persistent asthma were recruited from the Allergy, Asthma
and Dermatology Research Center in Lake Oswego, Ore-
gon, and Bensch Research Associates in Stockton, Cali-
fornia. Atopic status was conﬁrmed by skin test in 15 of
20 subjects, and by clinical assessment in the remaining
ﬁve subjects. Duration of disease ranged from 62 years to
1 year, with an average duration of 23 years. Ten of the
subjects were diagnosed with asthma as children. Asthma
subjects were categorized as mild persistent [N=4, forced
expiratory volume in 1s (FEV1)9 2  20%], moderate
persistent (N=11, FEV1 75 16%) or severe persistent
(N=11, FFEV1 65 17%) according to the 1997 NIH
Guidelines for the Diagnosis and Management of Asthma
[34]. Each clinical site’s Institutional Review Board or
Ethics Committee approved this study, and the only study-
speciﬁc procedure was sample collection. All asthma
subjects were on standard of care treatment: 14 subjects
were taking inhaled steroids, three were taking nasal
steroids and nine both inhaled and nasal steroids. Samples
collected included four (15%) from patients on oral
steroids. Eleven healthy volunteers were recruited from
Wyeth Research in Cambridge, MA, and had no known
history of asthma or seasonal allergies. Informed consent
was obtained from all subjects. Demographic information
for the subjects is shown in Table 1. Blood was drawn into
(8mL 6 tubes) cell puriﬁcation tubes (Becton Dickinson,
Franklin Lakes, NJ, USA). All asthma samples where
shipped at room temperature in a temperature-controlled
box overnight from the clinical site in the western US and
processed immediately upon receipt in Andover, MA
(approximately 24h after blood draw). Healthy subject
  c 2008 The Authors
Journal compilation   c 2008 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 38:1590–1605
In vitro allergen response and cPLA2a inhibition 1591samples, which did not require shipping, were stored
overnight before processing to mimic the conditions of
the asthma samples. Therefore, both groups of samples
were treated similarly to ensure that any observed differ-
ences between the groups were not attributable to differ-
ences in sample processing. PBMCs were isolated from
whole blood samples according to the manufacturer’s
recommendations.
In vitro cell stimulation
The PBMCs were stimulated in vitro (2 10
5cells/well, 96
well Costar-Corning CLS 3799) with a cocktail containing
four different allergens from house dust mite, ragweed
and cat. Recombinant allergens, Der p1, Der f2, Fel d1
(Indoor Biotech, Charlottesville, VA, USA) and natural
ragweed allergen (Allergy Lab, Seattle, WA, USA) were
screened for endotoxin levels (LAL Endotoxin Test, Cata-
log # HIT302, sensitivity, 0.0001EU/mL; Cell Sciences,
Canton, MA, USA), and allergen preparations were se-
lected based on having the lowest endotoxin levels among
available sources of these allergens. This was done to
ensure endotoxin levels as low as could be achieved using
puriﬁed natural allergens. The total level of endotoxin in
allergen-stimulated cultures was 0.057EU/mL, approxi-
mately 5.7pg/mL, about 100-fold below the reported
minimum required for endotoxin effects in vitro [35]. The
ﬁnal allergen cocktail concentrations in culture medium
were as follows: Der p1 and Der f2 (dust mite), 1mg/mL;
Fel d1 (cat), 1.25mg/mL; ragweed, 125mg/mL. Antigen
concentrations were chosen based on titration experi-
ments (twofold dilutions starting at 10mg/mL) performed
using samples from four human donors before the initia-
tion of work on the samples reported here. Optimal
concentrations were chosen based on maximum cytokine
production and antigen-dependent proliferation (data not
shown). A time course was also performed (from 3 to 7
days) and 6 days was chosen as optimal (data not shown).
The sensitivity of the subjects to the allergens used was
unknown, but allergens were chosen based on the esti-
mate that 80% of allergic individuals are believed to react
to one or more of these allergens [36]. Culture medium
contained RPMI-1640 (Sigma, St. Louis, MO, USA) with
10% heat-inactivated FCS (Sigma) and 100unit/mL peni-
cillin and 100mg/mL streptomycin and 0.292mg/mL glu-
tamine (GIBCO RL Invitrogen, Carlsbad, CA, USA).
The cPLA2a inhibitor, WAY-196025, was used at a
concentration of 0.3mM, and zileuton, the 5-lipoxygenase
inhibitor, at a concentration of 5mM in the PBMC samples.
The inhibitory activity of the batches of WAY-196025 and
zileuton used in this study was verified in a human whole
blood assay stimulated with calcium ionophore, A23187,
as described previously [37]. WAY-196025, was confirmed
to inhibit both the prostaglandin and leukotriene path-
ways with IC50o15nM and zileuton was shown to inhibit
the 5-lipoxygenase pathway with an IC50 of  0.55mM. The
characterization of WAY-196025 has been described else-
where [27]. In brief, WAY-196025 inhibits the production
of arachidonate metabolites – TXB2,L T B 4, PGE2 and
PGF2aby 72%, 78%, 79% and 72%, respectively, at 0.039mM
in A23187 stimulated human whole blood. WAY-196025
is selective for cPLA2a in cell-based assays, does not inhi-
bit COX-1 and COX-2 in microsomes, and is 41000-fold
selective against the closely related enzymes, cPLA2b and g.
The identity within the lipase domain between cPLA2a and
cPLA2b,a n dc P L A 2a and cPLA2z are 37% and 32%, respec-
tively [38]. Ghosh et al. [39] have reported the inhi-
bition of cPLA2z using an analogue of WAY-196025 they
called ‘Wyeth-1’, but the selectivity for WAY-196025
for cPLA2z was not tested in the work reported by
Ghosh et al. Within 10A ˚ of the active site Ser-228, 25 of
51 residues are distinct between cPLA2a and cPLA2z
a n d2 9o f5 1d i f f e rb e t w e e nc P L A 2a and cPLA2b.T o
ascertain directly if WAY-196025 inhibits cPLA2z
(PLA2G4F), Cos-M6 cells were transfected with pCMV6-
XL6-cPLA2z (Origene ACC#NM_213600), cleared lysates
were harvested and assayed using 1-palmitoyl-2-[
14C]ara-
chidonyl-sn-glycerophosphatidylcholine (PAPC) liposomes
as described previously for cPLA2b [ 4 0 ] .I na1 0m i ni n c u b a -
tion at 371C, 1mg of cleared lysate protein from cells
expressing cPLA2z released 16.5 times as much free arachi-
donate as lysate from mock-transfected cells showing that
the activity was due to cPLA2z. The amount of lysate had
been titrated to give  10% conversion of substrate. Using
these conditions in parallel assays performed in triplicate
containing either cPLA2a or cPLA2z, WAY-196025 inhibited
cPLA2a with an IC50=8n M with 90% inhibition observed at
30nM.I nc o n t r a s t ,c P L A 2z was inhibited only 30% at 2mM.
Higher concentrations of WAY-196025 were not tested
because 2mM is already 22% the concentration of the total
lipid (6mM PAPC and 3 mM dioleoyl glycerol) and therefore
may be acting to disrupt the surface of the liposome (data
not shown). Thus, WAY-196025 is minimally 250-fold
selective for cPLA2a.
After 6 days in culture, approximately 200mL of super-
natant was removed without disturbing the cell pellet
Table 1. Characteristics of study subjects
Healthy
volunteers (N=1 1)
Asthma
subjects (N=26)
Sex (M/F) 7/4 9/17
Race (Caucasian/Hispanic) 11/0 24/2
Age (y) 28–51 21–73
Asthma severity NA 4 mild
11 moderate
11 severe
M, male; F, female; y, years; NA, not applicable. Of the 20 atopics, allergy
assessments were done by skin test for 13, the remaining were
characterized as atopic through clinical assessment.
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tion plate for cytokine ELISA. To the remaining cell pellet,
100 mL of RLT lysis buffer containing 1% b-mercaptoetha-
nol was added and snap-frozen pending RNA puriﬁcation
(Qiagen, Valencia, CA, USA).
Cytokine assays
Levels of IFN-g, IL-5 and IL-13 in supernatants were
measured by ELISA. Supernatant was added to pre-coated
IFN-g, IL-5 and IL-13 ELISA plates (Pierce Endogen,
Meridain, Rockford, IL, USA) according to the manufac-
turer’s instructions. The appropriate biotinylated antibody
for each cytokine was used and streptavidin-HRP was
added and developed using 3,30, 5,50-tetramethylbenzi-
dine (TMB) substrate solution. Absorbance was measured
by subtracting the 550nm values from 450nm values.
Results were calculated using Softmax 4.7 software. The
sensitivity of the assays was also within the limits of the
manufacturer guidelines. The limit of detection was 2pg/
mL for IL-5, 7pg/mL for IL-13 and 2pg/mL for g-IFN.
Allergen-speciﬁc levels were determined by comparing
levels in the presence and absence of allergen. For a subset
of samples (N=17 for asthma and N=9 for healthy
subjects) for which sufﬁcient RNAwas available following
GeneChip analysis, levels of cytokine RNA expression
were measured using a custom Taqman low density array
(TLDA) described as follows.
RNA puriﬁcation and microarray hybridization
Total RNAwas isolated using the Rneasy mini kit (Qiagen).
A phenol/chloroform extraction was performed, and the
RNA was repuriﬁed using the Rneasy mini kit reagents.
Eluted RNA was quantiﬁed using a Spectramax96 well
plate UV reader (Molecular Devices, Sunnyvale, CA, USA)
monitoring A260/280 OD values. The quality of each RNA
sample was assessed by the integrity of the 28S and 18S
peaks by capillary electrophoresis alongside an RNA
molecular weight ladder on the Agilent 2100 bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). All proce-
dures for assaying samples on GeneChips were performed
by Expression Analysis (Expression Analysis, Inc. 2605
Meridian Parkway, Durham, NC, USA). Labelled targets for
oligonucleotide arrays were prepared using a modiﬁca-
tion of the procedure described by Lockhart et al. [41].
Labelled targets were hybridized to the HG-U133A Affy-
metrix GeneChip Array as described in the Affymetrix
technical manual. Eleven biotinylated control transcripts
ranging in abundance from 3 parts per million (ppm) to
100ppm were spiked into each sample to function as a
standard curve [42]. GeneChip MAS 5.0 software was used
to evaluate the hybridization intensity, compute the signal
value for each probe set and make an absent/present call.
Taqman low density arrays
Both to conﬁrm ﬁndings from GeneChip and to measure
levels of cytokine RNA that were below GeneChip levels
of detection, custom TLDA were designed using primers
and probes as listed through the Applied Biosystems
(Applied Biosystems, Foster City, CA, USA) website
(www.appliedbiosystems.com). A 48-assay design was
used and the individual assays are listed in supplementary
TableS1.Brieﬂy,forsampleswithsufﬁcientRNAremaining
following GeneChip measurements, 100ng of total RNA
was run for each sample per array and each sample was
run in duplicate. The samples assayed by TLDA were the
allergen-stimulated, allergen plus WAY-196025, and un-
stimulated sample sets from nine of the healthy and 17
asthma subjects. cDNA synthesis was carried out using a
high capacity cDNA archive kit (Applied Biosystems,
Product Number 4322171) according to the manufac-
turer’s protocols. Each cDNA sample (50mL) was added to
an equal volume of 2 TaqMan Universal PCR Master
Mix (Applied Biosystems) and the resulting mixture was
added to one of the eight channels on the array. The
samples were loaded by centrifugation into the wells that
contain the lyophilized primer probe sets. The card was
then sealed and PCR ampliﬁcation was performed using
an Applied Biosystems Prism 7900HT sequence detection
system according to the manufacturers protocols. (Ther-
mal cycler conditions were as follows: 2min at 501C,
10min at 94.51C, 30s at 971C, 1min at 59.71C for 40
cycles. All steps were carried out according to the manu-
facturer’s protocol).
Taqman low density array analysis
Expression values were calculated using the comparative
CT method as described (User Bulletin No. 2, Applied
Biosystems). Brieﬂy, this technique uses the formula
2 DDCT to calculate the expression of target genes normal-
ized to a calibrator. The threshold cycle (CT) indicates the
cycle number at which the amount of ampliﬁed target
reaches a ﬁxedthreshold. The CT values range from 0 to 40
(the latter representing the default upper limit PCR cycle
number that deﬁnes failure to detect a signal). The dupli-
cate samples were averaged, then the 2 DDCT value was de-
termined for each gene for each donor using the total gene
set average as the calibrator. The fold change was deter-
mined for each donor by the following formula: (2 DDCT
allergen treated 2 DDCT no treatment control)=log fold
change. The average log fold change was then determined
for the healthy volunteer group and for the asthma group
by averaging the individual fold changes.
Data normalization and ﬁltering of Affymetrix data
GeneChips were required to pass the pre-set quality
control criteria that the RNA quality metric required an
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40.4. The signal value for each probe set was converted
into a frequency value representative of the number of
transcripts present in 10
6 transcripts by reference to the
standard curve [42]. Data for 10280 probe sets that were
called ‘present’ in at least ﬁve of the samples and with
a frequency of 10ppm or more in at least one of the
samples were subject to the statistical analysis described
as follows, while probe sets that did not meet these criteria
were excluded.
Statistical analysis of Affymetrix data
The antigen-dependent fold change differences were cal-
culated by determining the difference in the log-2 fre-
quency in the presence and absence of antigen. ANOVA was
performed using this metric to identify allergen-depen-
dent differences, and also to identify significant differ-
ences between the asthma and healthy groups with respect
to the response to allergen. Raw P-values were adjusted
for multiplicity of testing according to the false discovery
rate (FDR) procedure of Benjamini and Hochberg [43]
using Spotfire (Somerville, MA, USA). Significant effects
of WAY-196025 were identified by ANOVA comparing the
log-2 differences in the groups treated with allergen to the
groups treated with allergen and WAY-196025.
Hierarchical clustering
For hierarchical agglomerative clustering of probe sets
and arrays, the log-2 scale MAS5 expression values from
each probe set were ﬁrst z-normalized so that each probe
set had a mean expression level of zero and a standard
deviation of 1 across all samples. Then, these normalized
proﬁles were clustered hierarchically using UPGMA (un-
weightedaveragelink)andtheEuclideandistancemeasure.
Ingenuity pathways analysis
Data were analysed through the use of Ingenuity Path-
ways Analysis (IPA) (Ingenuity
s Systems, Mountain
View, CA, USA (www.ingenuity.com). Asthma-associated
gene identiﬁers and corresponding expression and
P-values were uploaded into the application. Gene identi-
ﬁers were mapped to the corresponding gene objects in
the Ingenuity Pathways Knowledge Base. The Focus Genes
were overlaid onto a global molecular network developed
from information contained in the Ingenuity Pathways
Knowledge Base. Networks of these Focus Genes were
then algorithmically generated based on their connectiv-
ity. Functional analysis, canonical pathways and annota-
tions for these genes were also obtained using IPA.
Results
In vitro cytokine expression
We determined the allergen responsiveness of PBMC by
measuring the levels of cytokines produced by the PBMC
of asthma and healthy subjects following 6 days in vitro
stimulation. A 6 day time-point was chosen because at
both the mRNA [44] and protein levels [45], an effective
response to allergen has been previously demonstrated
and our pilot assays with protein and Taqman read-outs
before the initiation of this study conﬁrmed these results.
ELISA analyses were carried out for IFN-g, IL-5 and IL-13.
As shown in Table 2, all healthy volunteers and approxi-
mately 80% of asthma subjects showed a cytokine
response to allergen deﬁned as a 1.5-fold or greater
increase in the production of at least one cytokine
compared with baseline levels. Although the highest
levels observed for Th2 cytokines IL-5 and IL-13 were in
the asthma group and the highest levels of Th1 cytokine
IFN-g were observed in the healthy group, the statistical
power of this experiment was not sufﬁcient to detect a
signiﬁcant difference between these groups with respect
to allergen-speciﬁc cytokine production.
The samples were also treated with the cPLA2a inhibitor
WAY-196025 or zileuton in the presence of allergen and
cytokine measurements were taken. Both drugs signiﬁ-
cantly reduced IL-13 secretion (P-value=0.001 for the
WAY-196025 treatment and P-value=0.0005 for zileuton
Table 2. Cytokine production in healthy and asthma subjects
Cytokine
Healthy subjects Asthma subjects
Responders/
total tested
Range
without
allergen
(pg/mL)
Average
without
allergen
(pg/mL)
Range
with
allergen
(pg/mL)
Average
with
allergen
(pg/mL)
Responders/
total tested
Range
without
allergen
(pg/mL)
Average
without
allergen
(pg/mL)
Range
with
allergen
(pg/mL)
Average
with
allergen
(pg/mL)
IFN-g 11/11 (100%) 25–55 29 41–1080 343 17/23 (74%) 25–92 29 25–863 183.3
IL-5 4/11 (36%) 6–110 35 6–148 42.6 12/23 (52%) 6–284 44 6–243 60.3
IL-13 3/11 (27%) 25–699 149 24–305 118 13/23 (57%) 25–188 51.5 25–510 118
Production of cytokine was measured using ELISA assays on the supernatants from PBMCcultures after 6 day allergen stimulation as described in
‘Methods’. Subjects were classiﬁed as positive responders if, in the presence of allergen, cytokine production was increased at least 1.5-fold.
PBMC, peripheral blood mononuclear cell.
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niﬁcant effect on IL-5 or IFN-g levels (data not shown).
The 6-day cytokine RNA levels were also assessed using
the custom TLDA. Twelve cytokines and two cytokine
receptors were assayed: IFN-g, IL-10, IL-12B, IL-13, IL-15,
IL-17A, IL-18, IL-21, IL-32, IL-4, IL-5, IL-9, IL-13RA1 and
IL-21R. (Many of these genes were below the level of
detection of the Affymetrix GeneChip). The full list of
genes assayed by TLDA are listed in supplementary Table
S1. By RNA expression level as measured by TLDA, IL-15
(FDR=0.01), IL-18 (FDR=0.02), IL-13-RA (FDR=0.049)
had allergen-dependent changes that differed signiﬁ-
cantly (FDRo0.051) between asthma and healthy sub-
jects. The inhibition of cPLA2a had a signiﬁcant effect on
expression of both IL-15 (FDR=0.0007) and IL-18
(FDR=0.009) in this assay.
Peripheral blood mononuclear cell expression proﬁle
demonstrates response to allergen in both the healthy and
asthma groups following in vitro stimulation with allergen
Gene expression levels from the asthma (n=26) and
healthy subjects (n=11) were measured using Affymetrix
GeneChip. From the 10280 probe sets that met the inclu-
sion criteria described in ‘Methods’, we identiﬁed 130
probe sets (representing 123 unique genes) that demon-
strated a similar response to allergen in both the asthma
and healthy groups. Similar response to allergen was
deﬁned as an average allergen-dependent fold change
X1.5 in both groups, and no signiﬁcant difference
(FDR40.051) between the asthma and healthy groups
with respect to allergen-dependent changes. The complete
list of these 130 probe sets and their descriptions are
included in supplementary Table S2. Genes on this list
include IL-9 [46–49], IL-17 [50, 51], IL-22 [52–55] and IL-
26 [56, 57] and genes such as CXCL1, CXCL2 and CXCL3
[58, 59], immune system genes that are involved in
chemotaxis and activation of lymphoid cells, and MMP2
and MMP12 [60], implicated in degradation of the extra
cellular matrix.
Peripheral blood mononuclear cell expression proﬁle
distinguishes asthma patients from healthy volunteers
Comparison of the expression levels of the 10280 probe
sets in the asthma and healthy subjects identiﬁed 167
probe sets (representing 153 unique genes) whose aller-
gen-dependent changes differed signiﬁcantly (FDRo
0.051) between asthma and healthy subjects. These genes
also showed an allergen-dependent fold change 41.5 in
at least one group. The complete list of the 167 probe sets
and, for each, the signiﬁcance of the difference between
the groups is shown in supplementary Table S3. A
visualization of the differences between asthma and
healthy subjects with respect to allergen-dependent
changes in expression level of all 167 probe sets is shown
in Fig. 1. The visualization was generated using an
algorithm that groups subjects based on the similarities
with respect to allergen-dependent gene expression
changes. With one exception, all the healthy subjects were
grouped together, and 22 of the 26 asthma subjects were
grouped together. Table 3 shows 50 genes – a subset of
genes that showed a signiﬁcant difference between asthma
and healthy subjects with respect to the response to aller-
gen. The genes shown in Table 3 were associated with an
allergen response of 1.5-fold or more increase or decrease in
the asthma group, while having a o1.1-fold response to
allergen in the healthy volunteer population. In this list are
genes previously associated with the asthma phenotype
including the Zap70 and LCK tyrosine kinases [61], the toll-
like receptor 4 (TLR4) [62, 63], and complement component
3a receptor 1 (C3AR1) [64–68]. Allergen responsive genes
not previously shown to be involved in the asthma pheno-
type included sialoadhesin (SN1-CD163) [69], and a disin-
tegrin/metalloprotease, ADAM19 [70].
Conﬁrmation of the Affymetrix results was carried out
utilizing the custom TLDA described above using the sub-
set samples used in the Affymetrix-based experiment that
had sufﬁcient RNA remaining (n=19 for the healthy
group and n=9 for the asthma group. (See supplementary
Table S1 for genes assayed by TLDA). Twenty-ﬁve genes
were assayed both by GeneChip and by TLDA. The
concordance between platforms was assessed by compar-
ing the average allergen dependent log-2 fold change
metric as measured by GeneChip and the average aller-
gen-dependent DDCT metric as measured by TLDA. As
shown in Fig. 2, excellent correlation was observed
(Pearson’s correlation=0.910) indicating a tight concor-
dance in the results obtained from the two platforms.
While the power of the GeneChip and TLDA were not
comparable due to the differences in sample size and
therefore P-values cannot be directly compared, the trend
of the change was consistent for all genes. (The beneﬁt of
the increased sensitivity of the TLDA can be seen in the
results for IL-18, where the difference detected by Gene-
Chip did not pass the signiﬁcance ﬁlters but a signiﬁcant
difference was observed by TLDA.)
Because atopic subjects constituted the majority (77%)
of the asthma group and none of those in the healthy
group were atopic, we examined whether the differences
observed between asthma and healthy groups could be
attributable to atopy status rather than asthma. Compar-
isons between the healthy group and the asthma group
exclusive of the non-atopic group reduced the signiﬁcance
of association with the asthma in all cases, indicating that
the observed differences were not attributable to atopy
status (data not shown). Moreover, comparison of the
atopic and non-atopic proﬁles did not reveal genes
expressed at signiﬁcantly different levels between the
groups.
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In vitro allergen response and cPLA2a inhibition 1595A selective cPLA2a inhibitoralters the expression proﬁle of
allergen-responsive genes in asthma and healthy subjects
Treatment of allergen-stimulated samples with the
5-lipoxgenase inhibitor, zileuton, did not cause changes
that passed the ﬁlters set for signiﬁcant effect. In contrast,
the asthma-speciﬁc gene expression of a majority of the
167 probe sets associated with the asthma response to
allergen was altered signiﬁcantly in the presence of the
WAY-196025 cPLA2a inhibitor when compared with
allergen treatment alone. Results, including fold change
and signiﬁcance metrics in the comparison of groups with
and without cPLA2a inhibition, are shown in supplemen-
tary Table S4. The probe sets fall into three distinct
categories. In the ﬁrst category, probes that correspond to
genes that were up-regulated in asthma samples in re-
sponse to allergen, such as ZAP70, LCK and mini-chromo-
some maintenance protein (MCM2), are reduced to the
levels seen in the allergen-treated healthy controls. In the
second category, genes that were initially down-regulated
in the asthma samples in the presence of allergen, such as
sialoadhesin (SN), pleckstrin (PLEK) and PLAU are
up-regulated in the presence of inhibition. Lastly, there is
a group of genes that were down-regulated in the presence
of allergen in the asthmatic samples that are not affected
by cPLA2a inhibition, these genes include CD84 and tissue
inhibitor of metalloproteinase 3 (TIMP3).
Ahierarchicalclusteranalysiswasperformedtovisualize
the differences associated with cPLA2a inhibition for the
167 asthma-associated probesets(Fig. 3).This visualization
separated the asthma samples into the following three
groups based on similarities in gene expression pattern: (1)
asthma samples treated with allergen, (2) asthma samples
treated with allergen and WAY-196025 and (3) a small
population consisting of a mix of samples treated with
allergen or allergen1WAY-196025. Interestingly, group 3
contains the same subjects who originally clustered with
the healthy samples in response to allergen (see Fig. 1).
Functional annotation of gene expression
To explore the functional relatedness of the allergen-
responsive genes and identify associated pathways, the
asthma-associated allergen-responsive gene list (167
probe set) was functionally annotated using IPA. Of the
167 probes initially entered into the analysis, 127 met the
criteria for inclusion in pathway analysis. The criteria are
based on the ingenuity knowledge base and on our
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Fig. 1. Visualization of the allergen-dependent expression pattern of 167 probe sets that differ signiﬁcantly between asthma and healthy subjects:
subjects are shown in columns, and genes in rows. Red indicates an allergen-dependent change higher than the mean. Green indicates an allergen-
dependent change lower than the mean. Unsupervised clustering algorithm, which determines similarities between subjects independent of group
membership, was used to generate this visualization. Subjects are grouped according to the degree of similarity in expression pattern. Note that, with
one exception, the 11 healthy volunteers are grouped together, and that, with four exceptions, the 26 asthma subjects group together. H, healthy
volunteer; A, asthmatic. The numbers following the letters A or H correspond to the individual donor (ID).
  c 2008 The Authors
Journal compilation   c 2008 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 38:1590–1605
1596 K. A. Whalen et alTable 3. Gene expression differences between asthma and healthy subjects in response to allergen
Symbol Description Function
AOS fold
change
WHV fold
change
A
ZWINT ZW10 interactor Kinetochore function 1.78 1.08
FLJ23311 FLJ23311 protein DNA binding and inhibits cell growth 1.77 1.01
PRC1 Protein regulator of cytokinesis 1 Cytokinesis 1.74 1.09
CD28 CD28 antigen (Tp44) Antigen processing 1.74 1.09
PCNA Proliferating cell nuclear antigen DNA synthesis 1.73 1.03
RANBP5 Karyopherin (importin) beta 3 Nucleocytoplasmic transport 1.72 1.06
ZAP70 Zeta-chain (TCR) associated protein kinase 70kDa T cell function 1.72 1.00
CD3D CD3D antigen, delta polypeptide (TiT3 complex) T cell function 1.71 1.10
MELK Maternal embryonic leucine zipper kinase Stem cell renewal, cell cycle progression, and
pre-mRNA splicing
1.71 1.08
PRDX2 Peroxiredoxin 2 Potential antioxidant and antiviral 1.67  1.02
RACGAP1 Rac GTPase activating protein 1 Signalling 1.67 1.00
ITGA4 Integrin, alpha 4(antigen CD49D, alpha 4 subunit
of VLA-4 receptor)
Immune/inﬂammatory processes 1.66 1.07
PSIP1 PC4 and SFRS1 interacting protein 1 Transcription 1.66 1.01
TACC3 Transforming, acidic coiled-coil containing
protein 3
Centrosome/mitotic spindle apparatus 1.63 1.10
CD2 CD2 antigen (p50), sheep red blood cell receptor Immune cell mediator 1.62 1.10
BCCIP BRCA2 and CDKN1A interacting protein Cell cycle, tumor suppression 1.61  1.02
OIP5 Opa-interacting protein 5 Unknown, binds to bacterial protein 1.60 1.05
PRKDC Protein kinase, DNA-activated, catalytic
polypeptide
DNA damage/DNA synthesis 1.59 1.10
HNRPUL1 HeterogeneousnuclearribonucleoproteinU-like1 Nuclear RNA-binding protein 1.59  1.03
PSCDBP Pleckstrin homology, Sec7 and coiled-coil
domains, binding protein
Cytokine inducible-scaffold protein 1.58 1.01
IL21R Interleukin 21 receptor Proliferation and differentiation of immune cells. 1.55 1.07
PARP1 ADP-ribosyltransferase (NAD1; poly
(ADP-ribose) polymerase)
Cell differentiation, proliferation, and tumor
transformation DNA damage response
1.54 1.07
LCK Lymphocyte-speciﬁc protein tyrosine kinase T cell function/immune response 1.53 1.09
GPX7 Glutathione peroxidase 7 Oxidative stress response 1.53 1.06
RAD21 RAD21 homolog (S. pombe) DNA repair/mitosis 1.53 1.03
PTTG1 Pituitary tumor-transforming 1 Tumorigenic/chromatid separation 1.52 1.10
C6ORF149 Chromosome 6 open reading frame 149 Unknown 1.52 1.06
SNRPD3 Small nuclear ribonucleoprotein D3 polypeptide
18kDa
Pre-mRNA splicing and small nuclear
ribonucleoprotein biogenesis
1.52 1.03
FYN FYN oncogene related to SRC, FGR, YES Cell growth, immune cell signalling 1.51 1.02
B
GM2A GM2 ganglioside activator Glycolipid transport  2.05  1.02
SLC36A1 Solute carrier family 36 (proton/amino acid
symporter), member 1
Small amino acid transporter  1.90 1.01
TM6SF1 Transmembrane 6 superfamily member 1 Unknown  1.75  1.16
LCK Lymphocyte-speciﬁc protein tyrosine kinase T cell function/immune response  1.68 1.05
PYGL Phosphorylase, glycogen; liver (Hers disease,) Glycogen breakdown  1.68  1.10
PLEKHB2 Pleckstrin homology domain containing, family
B member 2
Vesicular proteins  1.67 1.06
CD84 CD84 antigen (leukocyte antigen) Cell adhesion  1.66  1.07
GCHFR GTP cyclohydrolase I feedback regulator Tetrahydrobiopterin biosynthesis.  1.65  1.03
SORT1 Sortilin 1 Lysosomal trafﬁcking  1.65  1.04
HLA-DQB1 Major histocompatibility complex, class II, DQ
beta 1
Antigen presentation  1.62  1.03
SLCO2B1 Solute carrier organic anion transporter family,
member 2B1
Organic anion transporting polypeptide  1.60  1.00
ZFYVE26 Zinc ﬁnger, FYVE domain containing 26 Unknown  1.59  1.02
TLR4 Toll-like receptor 4 Immune signalling receptor  1.56  1.01
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In vitro allergen response and cPLA2a inhibition 1597statistical ﬁlters as described above. Seven well-populated
functional networks were generated based on this infor-
mation. The top functions for the networks created using
IPA include immune and lymphatic system development
and function, immune response, DNA replication, recom-
bination and repair. The top-scoring network (Network 1)
consisted of 35 genes involved in immune response and
cell cycle (Fig. 4a). Genes in this network that were
up-regulated in the asthma compared with the healthy
subjects included the T cell receptor signalling genes
CD3D, CD28 and ZAP70 [71–73]. As expected, based on
the selection criteria, the expression levels (depicted by
the gene colour intensities) in Network 1 for the healthy
volunteer population looked very different from the
asthma subjects. However, in the healthy subjects, a few
of the genes were down-regulated in response to allergen
similarly to the asthma subjects, but to a signiﬁcantly
lesser extent. This set of genes includes cathepsin B
(CTSB), TIMP3 and CD36 antigen (collagen type I receptor,
thrombospondin receptor) (Fig. 4b).
The striking effect of cPLA2a inhibition on allergen-
induced asthma-associated gene expression changes can
be illustrated by utilizing IPA. In this analysis, the expres-
sion values obtained in the presence of the inhibitor were
overlaid into the gene set created based on asthma-
speciﬁc allergen gene changes. Every gene in Network 1
in the asthma group has an altered level of expression in
the presence of the inhibitor (Fig. 4c). In the healthy
population, the few genes that were down-regulated in
response to allergen in Network 1 are brought back to the
non-allergen-stimulated background levels in the pre-
sence of the inhibitor (data not shown).
Discussion
The study reported here was conducted to investigate (a)
how effects of in vitro exposure to allergen differ between
asthma and healthy subjects, and (b) the involvement of
the cPLA2a pathway in the processes identiﬁed as differ-
ent between the two groups. We approached these
important objectives by seeking to identify differences
between the healthy and asthmatic phenotypes at the
molecular level. Transcriptional proﬁling methods have
been employed in numerous previous studies as explora-
tory screening tools independent of pre-existing disease
paradigms [74–76]. This gene expression proﬁling study
was conducted to compare, at the gene expression level,
the response of asthmatic and healthy subjects PBMC
samples to in vitro stimulation with a cocktail of common
allergens. Subject samples in both groups responded to
Table 3. continued
Symbol Description Function
AOS fold
change
WHV fold
change
HLA-DMB Major histocompatibility complex, class II, DM
beta
Antigen presentation  1.56  1.01
RNF13 Ring ﬁnger protein 13 Unknown  1.56  1.08
PRNP Prion protein (p27–30) Prion diseases/oxidative stress  1.55  1.02
GAS7 Growth arrest-speciﬁc 7 Neuronal differentiation  1.53  1.10
ATP6V1A ATPase, H1transporting, lysosomal 70kDa, V1
subunit A
Acidiﬁcation of eukaryotic intracellular
organelles
 1.52 1.02
ATP6V0D1 ATPase, H1transporting, lysosomal 38kDa, V0
subunit d isoform 1
Acidiﬁcation of eukaryotic intracellular
organelles
 1.51  1.09
Probes(genes)thatchanged1.5-foldor greaterinthe asthmasubjects(AOS)butchangedlessthan 1.1-foldinthe healthyvolunteers(WHV),anFDRcut-
off of 40.051. (A) Genes up-regulated in asthma subjects 1.5-fold or higher compared with healthy volunteers. (B) Genes down-regulated by 1.5-fold or
more in asthma subjects compared with healthy volunteers.
FDR, false discovery rate.
Avg(LOGFC) for affymetrix
A
v
g
(
L
O
G
F
C
)
 
f
o
r
 
T
L
D
A
−3 −2 −1 0123
−6
−5
−4
−3
−2
−1
0
1
2
3
Fig. 2. The correlation of the average log fold of allergen/no allergen
gene expression between the Affymetrix GeneChip data and the low-
density array data for all subjects. The black diagonal line represents the
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measures of expression differences is 0.910. Affymetrix data is presented
as frequency and the Taqman low density array data is presented as the
DCT value.
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1598 K. A. Whalen et alallergen as assessed by allergen-dependent cytokine
stimulation both by ELISA, and, at the RNA level, by
TLDA. In addition, using both Affymetrix GeneChip and
TLDA platforms, we have identiﬁed many signiﬁcant
allergen-dependent gene expression differences between
the asthma and healthy groups, and those differences are
the focus of this study. We have extended this analysis
further to include the effects of inhibition of the cPLA2a
pathway on gene expression patterns signiﬁcantly asso-
ciated with the asthma group.
The speciﬁc allergens used in this study are common
environmental antigens and we report on many simila-
rities in the in vitro responses to allergen among asthma
and healthy subjects. Given the robust allergen responses
that did not differ signiﬁcantly between asthma and
healthy subjects, our data indicate that the standard of
care treatment that the asthma subjects were receiving did
not prevent robust responses in this 6 day culture experi-
mental system. Among genes that did not differ signiﬁ-
cantly between groups in the response to allergen are
some chemokines and ILs. Some of these genes have
previously been associated with the asthma phenotype
including those involved in the T cell response such as
IL-17 [77, 78] and IL-9 [49, 79] but in general, genes that
have previously shown to be involved in the asthma
subject response were modulated by allergen stimulation
to a greater extent in the asthma group than in the healthy
group. For example, the chemokine ligand 1 (CCL1) [80]
and CCL18 [81] have recently been shown to be involved
in the asthma phenotype and are up-regulated to a greater
extent in the asthma group. Also contained within this
gene set were genes not classically associated with the
immune response, including those involved in protective
stress responses such as the methallothionein (MT) gene
family, MT2A and MT1X [82, 83] as well as those involved
in glucose transport, GLUT-3 and GLUT-5 [84, 85]. Some
of the genes with similarly increased expression in the
presence of allergen in both the asthma and healthy
volunteer groups included red blood cell speciﬁc genes,
reﬂecting better 6 day in vitro survival of the small
percentage of contaminating red blood cells under condi-
tions of an in vitro immune response. This ﬁnding
indicates that at least some of the allergen-dependent
differential expression commonly observed in the two
groups was due to differences in culture conditions in the
presence and absence of an in vitro immune response to
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Fig. 3. Gene expression proﬁling demonstrates differential modulation of 167 probes in the asthma subjects in response to allergen in the presence of
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generate this visualization. Subjects are shown in columns, and genes in rows. Red indicates an allergen-dependent change higher than the mean. Green
indicates an allergen-dependent change lower than the mean. Subjects are grouped according to the degree of similarity in expression pattern: A,
asthmatic allergen-dependent fold change. A
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In vitro allergen response and cPLA2a inhibition 1599allergen. Such differences were, however, very similar in
the two groups, supporting the conclusion that response
to allergen occurred in both groups and that cell survival
was similar in both groups.
Although the asthma group contained a majority of
atopic subjects and the healthy group contained no atopic
subjects, our ﬁndings tend to support a conclusion that
the observed differences are attributable to asthma and
not to atopy status. If the ﬁndings were attributable to
atopy status, the signiﬁcance of the association for any
given gene with the group containing the aptopic samples
would be predicted to increase when the non-atopic
samples were excluded from analysis. The opposite was
the case – the signiﬁcance of association with the asthma
group decreased for all genes reported in supplementary
Table S3 when non-atopic asthmatics were removed from
the analysis. Moreover, a head-to-head comparison of
atopic (N=20) and non-atopic (n=6) subjects within the
Fig. 4. Allergen-responsive genes speciﬁc to the asthma group are modulated in response to the cPLA2a inhibitor. Network proﬁle generated by
Ingenuity Pathways Analysis(Ingenuity Systems). Genes are colour-coded according to whether they were up-regulated (red) or down-regulated (green)
in the asthmatic samples compared with the healthy volunteer samples. (a) Asthma-speciﬁc allergen response, (b) healthy volunteer speciﬁc allergen
response, (c) cPLA2a inhibitor affect on the asthma-speciﬁc allergen response. The symbols represent the type of protein that is coded for by the above
genes. Included are: Transporter, ; transcription regulator, ; phosphatase, n; enzyme/peptidase, }; other, .
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1600 K. A. Whalen et alasthma group failed to reveal any signiﬁcant differences.
While failure to detect such differences could be due to the
reduced power in this comparison, the results indicate that
the differences observed in the asthma vs. healthy com-
parison are not attributable to atopy.
Comparison of the expression levels of the 10280
probe sets in the asthma and healthy subjects identiﬁed
167 probe sets (representing 153 unique genes) whose
allergen-dependent changes differed signiﬁcantly (FDR4
0.051) between asthma and healthy subjects following
6 days in vitro stimulation. In addition, TLDA analysis also
identiﬁed IL-15, IL-18 and IL-13Ra1 as signiﬁcantly
associated with the response to allergen in the asthma
group. The identiﬁcation of a relatively large subset of
genes that distinguish between asthma and healthy sub-
jects in this in vitro study with relatively few subjects
underscores the power of the global proﬁling approach in
elucidating differences between groups that had not been
observed previously. In fact, despite the standard of care
therapy that the asthma subjects were receiving, several
genes were identiﬁed that were previously shown to be
involved in the asthma phenotype. These include comple-
ment C3AR1 [64–68] and the TLR4 [62, 63]. C3AR1 [86,
87] is involved in Th2 inﬂammatory responses [64]. C3AR
knockout mice challenged with allergens have a decrease
in AHR, airway eosinophils and IL-4 producing cells
relative to wild-type mice [64]. The TLRs are a family of
proteins that enhance certain cytokine gene transcription
levels in response to pathogenic ligands [88, 89], and TLR4
responds to endotoxin [90, 91]. Our data demonstrate that,
under these in vitro conditions (6 days in culture), the
TLR4 was differentially modulated in asthma subjects in
the presence of allergen. Recent evidence suggests that
TLR4 is important in the asthma phenotype, although the
data is conﬂicting [62, 92], but discrepancies may be
attributable to differences in experimental systems [93].
The results reported here implicate TLR4 as associated
with the asthma subjects’ in vitro response to allergen. In a
study comparing TLR4 expression levels in PBMC of
asthma and healthy subjects before culture, and TLR4
expression levels show a highly signiﬁcant association
with asthma (manuscript in preparation). Also included in
this list is the LCK tyrosine kinase. Two LCK GeneChip
probe sets give discordant results. Such discordant results
have been occasionally observed in other studies also, and
Taqman analysis has indicated that discordance can be
due to differences in expression of splice variants (data
not shown), although in the case of LCK, the explanation
of the discrepancy is unknown. TLDA analysis of LCK in
the study reported here indicates down-regulated in
asthma group.
The majority (approximately 80%) of the 167 differen-
tially regulated probes have not been previously shown to
be involved in the asthma phenotype. Among these are
ATPase transporters, ATP6V0D1, ATP6V1A and ATP6AP1
and the CD antigens, CD163, CD169, CD84 and CD59, and
PRNP, which is expressed on a variety of immune cell
types. Macrophages obtained from mice that do not
express PRNP have higher rates of phagocytosis than the
wild-type cells in vitro [94]. Available data on the im-
portance of macrophages in the asthmatic phenotype does
not inform on the signiﬁcance of macrophage PRNP in the
asthma phenotype [95]. However, alveolar macrophages
[96] play a role in innate immune responses and these
responses have been shown to affect the severity of
asthma [97] and bronchoconstriction in asthma [98].
Genes modulated in the allergen-treated PBMC of asthma
subjects that have not previously been associated with
asthma also include the following MCMs: MCM2, MCM5
and MCM7 along with polycomb group ring ﬁnger 4
protein, BMI1. BMI1 is involved in lymphoproliferation
[99] and is implicated in T cell differentiation [100].
Therefore, the lymphoproliferative effect of BMI1 could
be important in the asthmatic phenotype, perhaps playing
a role in increasing the amount of CD4
1 T cells in the
lungs of asthma subjects [101].
Global proﬁling also revealed allergen-dependent,
asthma-associated differential expression of several genes
involved in regulating the oxidative state that had pre-
viously not been associated with the asthma phenotype.
Reactive oxygen species are beneﬁcial in host defence
mechanisms. However, the production of these species can
be pro-inﬂammatory in diseases such as asthma. Included
among these are a glutathione peroxidase, glutathione
peroxidase 7 (GPX7), the nonselenoperoxidase, peroxire-
doxin 2 (PRDX2) and the microsomal glutathione S-trans-
ferase 3 (MGST3) gene. GPX proteins, such as GPX-1 have
previously shown to be responsible for suppression of 5-LO
activity in a monocytic cell line [102], but this is the ﬁrst
evidence that GPX7 may also be a factor in the asthmatic
response to allergen. MGST3 is responsible for the con-
version of LTA4 to LTC4, and both are important mediators
of the arachidonic acid pathway. Lastly, the peroxiredoxin
family of proteins are responsible for the reduction of a
broad spectrum of peroxides [103] and have been shown
to be up-regulated in lung carcinomas [104], but have not
previously been associated with asthma.
cPLA2a catalyses the ﬁrst step in the biosynthesis of
arachidonic acid-derived leukotrienes and prostaglandins
[24, 25] and is theoretically an attractive target for
inhibition in the treatment of inﬂammatory diseases
[105]. Anti-leukotriene therapy acting either at the level
of 5-lipoxygenase or CysLT1 receptor has proven bene-
ﬁcial in the treatment of asthma [106]. Prostaglandin D2
and other prostaglandins may also mediate the hallmarks
of asthma including airway inﬂammation AHR and
bronchoconstriction [107]. cPLA2a knock-out mice are
resistant in mouse model of asthma [105], and inhibitor
WAY-196025 used in this study [27] and other cPLA2a
inhibitors have shown efﬁcacy in animal models of
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system was used in this study to evaluate the molecular
effects of cPLA2a inhibition in PBMCs. The inhibition of
cPLA2a had striking effects on the allergen-related, asth-
ma-associated proﬁle. The hierarchical clustering analysis
revealed that cPLA2a inhibition affected a shift in the
asthma-associated allergen-dependent proﬁle to a proﬁle
closely resembling the proﬁle of healthy volunteers with
approximately 80% of the probes changing signiﬁcantly
(FDR40.051) with treatment. As discussed in ‘Results’ and
shown in Fig. 4c, all T cell responsive genes in the
pathway depicted in Fig. 4a were signiﬁcantly changed
towards the levels in the healthy subject group by cPLA2a
inhibition. This result is noteworthy given that CD4
1
T cells are believed critical for the development and
maintenance of the disease [109]. Other immune-related
genes were also down-regulated by cPLA2a inhibition
including, CD28 and CD3D, IL-21R and the transcription
factor, high-mobility group box 1 protein (HMGB1). The
HMGB1 result is of particular interest as this protein has
been shown to be a distal mediator of acute inﬂammation
of the lung linked to an increased production of pro-
inﬂammatory cytokines [110].
The effect of cPLA2a inhibition on gene expression is
more noteworthy in that it was not replicated by zileuton
– suggesting that the effect seen with cPLA2a inhibition
is not strictly mediated by leukotrienes, but is at least
partially due to the inhibition of a greater range of lipid
mediators including the prostaglandins, platelet-activat-
ing factor and products of 12 and 15-lipoxygenases [27,
30]. As mentioned above, the effects of zileuton on gene
expression did not pass the ﬁlters set for signiﬁcance in
the GeneChip portion of the study and are much more
subtle. However, protein analysis revealed a signiﬁcant
effect of zileuton on IL-13 production at the 6 day time-
point assayed, indicating that gene expression changes
may have been detectable at earlier untested time-points.
Peripheral blood is easily accessible, and the transcrip-
tome of PBMCs can be studied both directly upon collec-
tion and following in vitro stimulation. We have employed
an in vitro model system to identify disease-related
transcriptional proﬁles and to model the response of
PBMCs in the clinical setting to drug exposure using an
experimental inhibitor of cPLA2a. The results of this
global proﬁling study have yielded broad ranging ﬁnd-
ings on the signiﬁcant differences and similarities
between asthma and healthy subjects as revealed by in
vitro allergen responsiveness. The scope and size of the
study have allowed us to conﬁrm some previously re-
ported asthma associations, and to discover novel asso-
ciation that were not predictable based on the pre-existing
information. These results clearly demonstrate that global
transcriptional proﬁling has utility as a sensitive explora-
tory tool to study molecular mechanisms of disease and
pathways affected by candidate therapeutics.
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